CN1634555A - Medicine for treating chronic gastritis - Google Patents
Medicine for treating chronic gastritis Download PDFInfo
- Publication number
- CN1634555A CN1634555A CNA2003101222400A CN200310122240A CN1634555A CN 1634555 A CN1634555 A CN 1634555A CN A2003101222400 A CNA2003101222400 A CN A2003101222400A CN 200310122240 A CN200310122240 A CN 200310122240A CN 1634555 A CN1634555 A CN 1634555A
- Authority
- CN
- China
- Prior art keywords
- strain
- treatment
- chronic gastritis
- medicine
- fermentation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention relates to a therapeutic medicine for chronic gastritis characterized in that No.33 bacterial of alpha streptococcus hemolyticus is carried to outer space by go and back type deep space vehicle, and heredity mutation thereof occurs under the special condition of the outer space. Bacterial with positive variation and stable heredity are optimized and go through the culturing and fermenting process to prepare biochemical formulation for the treatment of chronic gastritis. The bacterial is preserved by China General Microbiological Culture Collection Center with serial number of CGMCCNo. 1082. Said biochemical preparation for the treatment of chronic gastritis is oral liquid containing mannan peptide 0.8g to 15.0g produced by outer space mutated bacterial in 1000 ml thereof.
Description
Technical field
The present invention relates to a kind of medicine, particularly about a kind of medicine that is used for the treatment of chronic gastritis.
Background technology
Chronic gastritis is a commonly encountered diseases, and internal medicine does not still have the specific treatment medicine at present, and Therapeutic Method reduces avoids the cause of disease, is that basis and proton pump preparation are the two big classes on basis with the colloidal bismuth.Treatment by Chinese herbs is only effective to the part patient, is generally acknowledged both at home and abroad to be listed as yet and incorporates conventional treatment into.Still have any problem though A type gastritis is improved but gastric mucosa Regeneration and Repair, atypical hyperplasia are disappeared through above-mentioned treatment most of patients symptom, domestic do not have relevant report yet, and certain toxic and side effects is arranged.The medicine mannatide that common alpha-Hemolytic streptococcus is produced for No. 33 is listing at home as far back as 1986, it is only as a kind of immunostimulant, pharmacological action is an activated lymphocyte, promote the thymic lymphocytes differentiation and proliferation, promote the antineoplastic immune function of body, activating macrophage, leukocyte is generated to be increased, promote complement to generate, promote the generation of interleukin-1, improve hemopoietic function of bone marrow.And do not have as the medicine for the treatment of the ulcer colon.
Summary of the invention
The purpose of this invention is to provide a kind of medicine for the treatment of chronic gastritis, its adopts biochemical preparation treatment chronic gastritis, has nontoxicly, and side effect is little, the characteristics that effective percentage is high.
Technical scheme of the present invention is a kind of medicine for the treatment of chronic gastritis of design, it is characterized in that: it carries the reciprocation type space craft with No. 33 strains of Alpha-hemolytic streptococcus, under the specific condition of space, cause No. 33 strain hereditary properties of Alpha-hemolytic streptococcus to morph, optimize plus variant wherein, the strain of stable hereditary property, after cultivating fermentation, produce the biochemical preparation of treatment chronic gastritis, this strain is numbered CGMCCNo.1082 through China Committee for Culture Collection of Microorganisms's common micro-organisms center preservation.
The biochemical preparation of described treatment chronic gastritis is an oral liquid, contains the mannatide 0.8g-15.0g that the space flight strain is produced among the 1000ml.
Described oral liquid is that No. 33 strains of Alpha-hemolytic streptococcus carry reciprocation type space craft, variation, the strain after preferred, through cultivating the production stock solution of fermentation, adds other attached material.
Described oral liquid is that No. 33 strains of Alpha-hemolytic streptococcus carry reciprocation type space craft, variation, the strain after preferred, through cultivating the production stock solution of fermentation, adds the purified water dissolving and stirs evenly.
Described attached material be essence and, smart sodium, protein sugar.
Described attached material is an active carbon.
The preparation method of described mannatide is; Preferred alpha-Hemolytic streptococcus 33 strains carry out space treatment, and No. 33 bacterium pearls of alpha-Hemolytic streptococcus of the meticulous selection-breeding of process space flight are as the production strain preparation; Through one grade fermemtation and second order fermentation, fermentation liquid to be purified, final production goes out the mannatide that the space flight strain is produced.
Described strain preparation:
A. inclined-plane seed culture medium: Carnis Bovis seu Bubali cream 0.2-0.8%, yeast extract 0.2-0.8%, peptone 0.3-0.8%, glucose 0.1-0.8%, sodium chloride 0.2-0.6%, agar 1-5%, sheep blood 5-10%; PH7.2-7.4;
105-125 ℃ of inclined-plane seed culture medium sterilising temp, 30 minutes time, steam pressure 0.11-0.14Mpa;
Unpacking strain cryovial, with aseptic broth bouillon dilution, access blood inclined-plane under aseptic condition, inoculate rearmounted 25-40 ℃ constant temperature culture 24-30 hour;
B. meat soup seed culture medium: Carnis Bovis seu Bubali cream 0.2-0.8%, yeast extract 0.2-0.8%, peptone 0.3-0.8%, glucose 0.1-0.8%, sodium chloride 0.2-0.6%; PH7.0-7.4;
105-125 ℃ of meat soup seed culture medium sterilising temp, 30 minutes time, steam pressure 0.11-0.14Mpa; Cultured slant strains is pressed the 1-9% inoculum concentration insert in the meat soup seed culture medium under aseptic condition, 25-40 ℃ constant temperature culture 10-30 hour.
Described sweat fermentation medium; Carnis Bovis seu Bubali cream 0.2-0.8%, yeast extract 0.2-0.8%, peptone 0.3-0.8%, glucose 0.1-0.9%, sodium chloride 0.2-0.6%; 105-125 ℃ of fermentation medium sterilising temp, 30 minutes time, steam pressure 0.11-0.14Mpa;
A. one grade fermemtation jar: good meat soup strain is pressed the 1-10% inoculum concentration insert first class seed pot under aseptic condition, at 25-40 ℃ of constant temperature culture 10-50 hour, tank pressure was no more than 0.02Mpa, and ventilation is advisable can stir culture fluid, fully stirred continuously;
B. second order fermentation jar: the one grade fermemtation culture fluid is pressed the 2-20% inoculum concentration insert fermentation tank under aseptic condition, at 25-40 ℃ of constant temperature culture 20-100 hour, tank pressure was no more than 0.02Mpa; Jar is put in deactivation, and deactivation is adopted to heat and made the fermentation liquid temperature reach 70-120 ℃, is incubated 20-60 minute, and cooling is left standstill.
10, a kind of medicine for the treatment of chronic gastritis according to claim 1 is characterized in that:
Described leaching process;
A, fermentation liquid concentrate, and make concentrated solution volume and fermentating liquid volume ratio be controlled at 1: 15-1: 20 or be determined by circumstances;
The concentrated solution of b, fermentation liquid adds 80-99% ethanol, and the volume ratio is controlled at 1: 1.5-1: 5.5 or be determined by circumstances, fully stir leave standstill after, centrifugal removal supernatant, the precipitation dissolved in distilled water, accent pH1.0-5.0 obtains lysate and lysate is left standstill;
C, the more centrifugal removal impurity of lysate is obtained supernatant, accurately measure the supernatant volume, calculate required amount of alcohol, ethanol is slowly joined in the supernatant, and fully stir, leave standstill the centrifugal removal supernatant in back and obtain precipitate by the supernatant stereometer;
D, precipitate reuse dissolved in distilled water are transferred pH, centrifugal, and supernatant adds ethanol precipitation again, such technology repeatable operation to content detection qualified till, the precipitate that obtains is the mannatide crude product that the space flight strain is produced; Promptly got the mannan peptide product that the space flight strain is produced in vacuum drying 3-8 hour.
Characteristics of the present invention are: because the present invention is carried recoverable space craft (spacecraft or retrievable satellite) with the Alpha-hemolytic streptococcus strain, utilize the comprehensive function of factors such as little in the space (zero) gravity, cosmic ray, alternating magnetic field, fine vacuum, hyperpyrexia deep cooling, make the dna double chain structure fracture of bacterial strain, genome is reset, thereby produces new bacterial strain.After returning ground, bacterial strain through space treatment is cultivated and screened, by studying contents such as its morphological characteristic, cultural characteristic, biochemical reactions, metabolite, hereditary character and protein expression, hereditary stability, pilot scale production target, optimize the stable strain of plus variant, inherited character wherein, the medicine of the chronic gastritis that after cultivation and fermentation, obtains medical treatment.This strain in China Committee for Culture Collection of Microorganisms's common micro-organisms center preservation, is numbered CGMCCNo.1082.
Particularly Alpha-hemolytic streptococcus D33 bacterial strain behind ground screening, separation and the purification, selects higher, the secreted mannan peptide content of fermentation unit higher high yield, quality strains T33 strain through space treatment mutation.By Institute of Microorganism, Academia Sinica whole-cell protein SDS-polyacrylamide gel (SDS-PAGE) analysis of T33 bacterial strain and D33 bacterial strain and the genomic DNA restricted enzyme cutting analysis (RFLP/PFGE) of bacterial strain are compared, can prove that its gene of T33 bacterial strain that space mutagenesis and ground filter out has variation.This mutant strain is stable in heredity, stronger production adaptability is arranged, the mannan peptide content that is produced by its fermentation improves, content of peptides improves 3 to 5 times than national standard (80%), institute for drug control, Xi'an sample presentation is measured and is reached 271.6%, and fermentation content on average exceeds more than three times than matched group product content.This bacterial strain has significant curative effect through the oral liquid that high-tech means such as cultivating, ferment, purify and be refining is prepared to the treatment chronic gastritis.Through collecting the patient medical record data of taking medicine in a large number, further investigation conclusion summary promotes the effect of gastric mucosa Regeneration and Repair through collecting the patient medical record data further investigation conclusion summary alleged occurrence of taking medicine in a large number, has the effect of the gastric mucosa of promotion Regeneration and Repair.
(see Appendix: adnexa material 1: science and technology bureau Shaanxi Province, Shaanxi Province scientific and technological achievement assay certificate material
Adnexa material 2: the mannatide that the space flight strain is produced is produced bacterial strain and is carried notarization through " No. three, divine boat " airship.
Adnexa material 3: the mannatide that the space flight strain is produced is produced bacterial strain and is returned ground screening report through the lift-launch of " No. three, divine boat " airship
Adnexa material 4: Microbe Inst., Chinese Academy of Sciences produces the form Physiology and biochemistry probation report book of bacterial strain and ground contrast bacterium about the mannatide that " No. three, divine boat " airship carries the production of space flight strain
Adnexa material 5: Microbe Inst., Chinese Academy of Sciences produces SDS-PAGE and the RFLP/PFGE Analysis and Identification statement of bacterial strain and ground contrast bacterium about the mannatide that " No. three, divine boat " airship carries the production of space flight strain
Adnexa material 6: the mannatide oral liquid examining report that institute for drug control, Shaanxi Province " No. three, divine boat " space flight strain is produced
Adnexa material 7: scientific and technological novelty assessment report copy
Adnexa material 8: the notice copy is accepted in China Committee for Culture Collection of Microorganisms's common micro-organisms center preservation culture presevation)
New pharmacological action analysis of experiments checking: the enhance immunity effect of the mannatide that the infective agent of chronic gastritis can be produced by the space flight strain is eliminated.But the intestinal epithelial metaplasia and atypical hyperplasia and the false pylorus glandular metaplasia that occur in the chronic gastritis progress stimulate collective's immune system generation parietal cell antibody relevant with intrinsic factor antibody with the impaired autoantigen of parietal cell.The use enhance immunity is failed to respond to any medical treatment.The mechanism of the mannatide treatment chronic gastritis mucosa infection of space flight strain production is to promote the gastric mucosa Regeneration and Repair, and by promoting gastric epithelial cell hypertrophy differentiation and maturation, regeneration is quickened.Reverse intestinal epithelial metaplasia and atypical hyperplasia and false pylorus glandular metaplasia and realize.Zoopery verification table skin growth factor EGF is active in the group of taking medicine obviously to be strengthened.The typical chronic gastritis mucosa infection that the excision rat submandibular gland is brought out can be eliminated by the mannatide of oral space flight strain production.And the physiological action of epidermal growth factor EGF in digestive tract is to activate ODC Ornithine decarboxylase ODC, promotes the mucosa cell DNA synthetic.The gastric acid inhibitory secretion.Promote epithelial proliferation.Increase gastric mucosal blood flow.Promote transhipment and the utilization of intestinal mucosa to glutamine.
New purposes checking: through using the mannatide oral liquid patient's of " No. three, divine boat " space flight strain production investigation to find that 778 routine various chronic inflammatory disease patients merge digestive tract function obstacle person to 1,000 examples, upper abdomen is glutted after the meal after the week of taking medicine, irregularities dull pain, belch, acid regurgitation, burn feeling, inappetence, feel sick transference cures such as vomiting.Wherein recurrent respiratory tract infection merges chronic gastritis person's 543 examples, chronic cholecystitis postcholecystectomy syndrome 59 examples, person's 96 examples that senile osteoarthritis takes the antipyretic analgesic, other 80 examples.Previously clear and definite upper gastrointestinal hemorrhage medical history person 26 examples are arranged, excessive drinking history person 4 examples are arranged.Pay a return visit after three months and adhere to that 681 routine patient's symptoms of taking medicine do not have repeatedly, 66 examples that have gastroscope to clarify a diagnosis before wherein taking medicine, the back check gastroscope gastric mucosal lesion disappearance mucosa of taking medicine recovers normal.
New curative effect checking: Chen Chengli, man, 45 years old.Live Xi'an Nan Yaotoucun.Chronic atrophic gastritis 8 years.Abdominal distention, acid regurgitation, anorexia, anemia, the weak clothes plurality of Chinese of seriously becoming thin is invalid.Make gastroscope in No.1 affiliated Hospital, Xian Medical Univ. before 8 years and be diagnosed as first type gastritis.The check gastroscope sees that the gastric body mucosa atrophy is red and white with Bai Weizhu before 2 years, and pleat is smooth can see blue color stria vascularis, intestinal epithelial metaplasia, severe atypical hyperplasia thoroughly.HP(+)。No. three oral liquids of clothes divine boat are the appetite recovery after one course of treatment, and appetite is increased to seven liang from three liang of every days.Energetic, no matter dysstasia after the cause of taking medicine is too become thin and squatted down is to change position after taking medicine, and still is engaged in light moderate physical work and does not all feel tired.Back four months check gastroscope gastric mucosas of taking medicine are crocus, and the plentiful traveling rule of pleat is not seen intestinal epithelial metaplasia and atypical hyperplasia, HP (-).Clinical judgment is recovery from illness.The beam kiosk, the man 68 years old, lives Xi'an No. 90 mailbox family members institute.Suffer from cold whenever over past ten years and the raw and cold food of taking food after belch, pantothenic acid promptly appear having a stomach-ache.Make gastroscope in second Affiliated Hospital of peace medical university and be diagnosed as chronic superficial gastritis, see under the mirror that false pylorus glandular metaplasia uses multiple stomach medicine therapeutic effect undesirable.The beginning of September is taken No. three oral liquids of divine boat, and above-mentioned symptom is clearly better after the week, and stomach discomfort disappears.The check gastroscope is not seen mucosa infection after three months.
Specific embodiments
Strain improvement: on the basis of Alpha-hemolytic streptococcus growth rhythm, selected than the proper growth strain in period, adopt the plate growth bacterium colony, immerse methods such as the bacteria suspension in other material, germ-carrying sand, carry " No. three, divine boat " spacecraft on March 25th, 2002.Carried out 6 days 0 18 hours flying at space track (200 kilometers of perigee altitudes, 350 kilometers of altitude of the apogees) at rail.The specific condition of space mainly is presented as special environments such as microgravity, fine vacuum, high radiation, alternating magnetic field.The strain of outer-space flight be placed in one with the diverse environment of tellurian ecological environment in, the electronics, proton and the mental retardation heavy particle that mainly comprise coming self-magnetic field to capture; Cosmic ray such as proton, particle and heavier high energy heavy particle from the milky way galaxy; From the proton of sun magnetic storm and heavy particle etc.These particles act on the dna double chain structure in the microbial cell nuclear, can cause double-strand break.Microgravity, high vacuum environment can make the base sequence of DNA recombinate, promptly genomic reorganization and variation.The new bacterial strain that the variation back produces, variation in various degree all can take place in its morphological characteristic, cultural characteristic, biochemical reactions, metabolite, hereditary character and protein expression, pilot scale production target etc.After ground is returned in spacecraft, through further screening, only optimize wherein 0.2% plus variant and the stable bacterial strain of inherited character, make the production strain through cultivation.This strain that after spaceship-carried mutation, selects December in 2003 29 days by China Committee for Culture Collection of Microorganisms's common micro-organisms center preservation, be numbered CGMCCNo.1082.
Experiment and middle trial production result show, stable on inherited character through the novel space strain behind the space mutagenesis, stronger production adaptability is arranged, the mannan peptide content that is produced by its fermentation improves, content of peptides improves 3 to 5 times than national standard (80%), institute for drug control, Xi'an sample presentation is measured and is reached 271.6%, and fermentation content on average exceeds more than three times than matched group product content, and fermentation period shortens greatly.
Preparation method:
The space flight strain is produced the preparation process of mannatide:
The mannatide of space flight strain of the present invention production is by following method preparation: the space strain preparation--purify, and final production goes out mannatide by one grade fermemtation--second order fermentation----fermentation liquid.
1. space strain preparation:
With through the Alpha-hemolytic streptococcus of space mutagenesis breeding meticulous selection-breeding as producing strain.
A. inclined-plane seed culture medium: Carnis Bovis seu Bubali cream 0.5%, yeast extract 0.6%, peptone 0.5%, glucose 0.4%, sodium chloride 0.5%, agar 3%, sheep blood 8%; PH7.4.
121 ℃ of inclined-plane seed culture medium sterilising temps, 30 minutes time, steam pressure 0.12Mpa.
Unpacking strain cryovial with aseptic broth bouillon dilution, inserts the blood inclined-plane under aseptic condition, the rearmounted 38 ℃ of constant temperature culture of inoculation 30 hours.
B. meat soup seed culture medium: Carnis Bovis seu Bubali cream 0.5%, yeast extract 0.6%, peptone 0.5%, glucose 0.4%, sodium chloride 0.5%; PH7.4.
121 ℃ of meat soup seed culture medium sterilising temps, 30 minutes time, steam pressure 0.12Mpa.
With cultured slant strains under aseptic condition by 9% inoculum concentration, insert in the meat soup seed culture medium 38 ℃ of constant temperature culture 30 hours.
2. sweat:
Fermentation medium: Carnis Bovis seu Bubali cream 0.4%, yeast extract 0.5%, peptone 0.5%, glucose 0.4%, sodium chloride 0.5%.
121 ℃ of fermentation medium sterilising temps, 30 minutes time, steam pressure 0.12Mpa.
A. one grade fermemtation jar: with good meat soup strain under aseptic condition by 10% inoculum concentration, insert first class seed pot, 29 ℃ of constant temperature culture 30 hours, tank pressure was no more than 0.02Mpa, ventilation is advisable can stir culture fluid, fully stirs continuously.
B. second order fermentation jar: with the one grade fermemtation culture fluid under aseptic condition by 20% inoculum concentration, insert fermentation tank, 29 ℃ of constant temperature culture 70 hours, tank pressure is 0.02Mpa not, jar is put in deactivation.Deactivation is adopted to heat and is made the fermentation liquid temperature reach 100 ℃, is incubated 60 minutes, and cooling is left standstill.
3. leaching process:
A, fermentation liquid concentrate, and make concentrated solution volume and fermentating liquid volume ratio be controlled at 1: 15-1: 20 or be determined by circumstances.
The concentrated solution of b, fermentation liquid adds 80-99% ethanol, and the volume ratio is controlled at 1: 1.5-1: 5.5 or be determined by circumstances.Fully stir leave standstill after, centrifugal removal supernatant, the precipitation dissolved in distilled water, accent pH5.0 obtains lysate and lysate is left standstill.
C, the more centrifugal removal impurity of lysate is obtained supernatant, accurately measure the clear liquid volume, calculate required amount of alcohol by the supernatant stereometer, adjust pH slowly joins ethanol in the supernatant, and fully stirs, and leaves standstill the centrifugal removal supernatant in back and obtains precipitate.
D, precipitate reuse dissolved in distilled water are transferred pH, and centrifugal, supernatant adds ethanol precipitation again.Such technology repeatable operation to intermediate detection qualified till, the precipitate that obtains is the mannatide crude product that the space flight strain is produced.Vacuum drying 3-8 hour, promptly obtain the mannan peptide product that the space flight strain is produced.
The check of the product that said method obtains:
[character] this product is white or little yellow amorphous powder; Odorless, tasteless.
This product is easily molten in water, and is insoluble in ethanol, chloroform and acetone.
Specific optical rotation: get this product, accurate claim surely, be dissolved in water and be diluted to the solution that contains 10mg among every 1ml approximately, measure (two appendix vIE of Chinese Pharmacopoeia version in 2000) in accordance with the law, specific optical rotation is+70 ℃ to+80 ℃.
[discriminating] 1, get this product 10mg, add water 0.5ml and make dissolving, add a-naphthols alcoholic solution (5-100) 1ml, shake up, slowly add sulphuric acid 0.5ml along tube wall, after several minutes, the interface is aubergine.
2, get this product, add water and make the solution that contains 1mg among every 1ml, get about 10ul point on filter paper, dry, fix, put high salpeter solution and (get periodic acid 1.2g with dehydrated alcohol, after adding water 30ml dissolving. add 0.2mol/L sodium acetate solution 1.5ml and ethanol 100ml, mixing is promptly.Put the dark place and preserve, can use the several months) the middle immersion 5 minutes, take out, wash with 70% alcoholic solution, (get potassium iodide 5g, sodium thiosulfate 5g adds water 100ml and makes dissolving to put reducing solution, add ethanol 150ml, 2mol/L hydrochloric acid solution 2.5ml again, with adding, face the time spent and join with stirring) the middle immersion 5 minutes, take out, wash with 70% alcoholic solution, put in the pinkish red industry sulphuric acid test solution and soaked about 30 minutes, take out, (get sodium pyrosulfite 0.4g with sodium metabisulfite solution, add hydrochloric acid 1ml, being dissolved in water makes into 100ml, promptly), and flushing, dry, the place should be aubergine at the filter paper point sample.
3, get test sample and reference substance is an amount of, add respectively the chlorination sodium injection make contain 1mg among every 1ml solution as need testing solution and reference substance solution, press the test of mannatide immunogenicity determining method, test sample and contrast QC should all not have haemolysis to be taken place.
[inspection] 1, acidity: get this product, add water and make the solution that contains I0mg among every 1ml, measure (two appendix VIH of Chinese Pharmacopoeia version in 2000) in accordance with the law, pH value should be 3.0-5.0.
2, trap: get this product, add water and make the solution that contains 0.4mg among every 1ml, according to spectrophotography (two appendix VIA of Chinese Pharmacopoeia version in 2000), wavelength place at 260nm, its trap must not be greater than 0.25, and at the wavelength place of 280nm, its trap must not be greater than 0.20.
3, total nitrogen: get this product, measure according to N2 method (two appendix VIID second methods of Chinese Pharmacopoeia version in 2000). press dry product and calculate, contain total nitrogen and should be 0.8-2.0%.
4, immunogenicity: get test sample and reference substance is an amount of, add the chlorination sodium injection respectively and make the solution that contains 10mg among every 1ml, make 1: 2,1: 4,1: 8,1: 16,1: 32,1: 64,1: 128,1: 256 diluent as need testing solution and reference substance solution with phosphate buffer respectively again, check in accordance with the law (attached mannatide immunogenicity determining method) that the least concentration of the insoluble blood vessel of test sample should be higher than more than a times of reference substance respective concentration.
5, loss on drying is got this product, is dried to constant weight at 105 ℃, subtracts weight loss and must not cross 5.0% (two appendix VIIIL of Chinese Pharmacopoeia version in 2000).
6, heavy metal is got this product, at 1.0g, checks that in accordance with the law (Chinese Pharmacopoeia version VIIIH in 2000) contains heavy metal and must not cross 20/1000000ths.
7, the undue toxicity gets this product, adds the chlorination sodium injection and makes the solution that contains 0.5mg among every 1ml, checks (Chinese Pharmacopoeia version appendix in 2000 XIC) in accordance with the law. press the intravenous injection administration, and should (injection) up to specification.
[assay]
1. the preparation of reference substance solution
Precision takes by weighing through 105 ℃ of D-mannose reference substance 0.1g that are dried to constant weight and puts in the 100ml measuring bottle, is dissolved in water and is diluted to scale. shake up; Precision is measured 5ml, puts in the measuring bottle of 100ml, adds water to scale, shakes up. contain mannose 50ug among every 1ml.
2. need testing solution is equipped with
It is an amount of to get this product, and accurate the title decides, and is dissolved in water and makes the solution that contains 40ug among every 1ml.
3. the preparation of standard curve
Precision takes by weighing reference substance solution 0,0.2,0.4,0.6,0.8,1.0ml, put respectively in the tool plug test tube, respectively add water to 1.0ml, add 3% phenol solution 1.0ml again, shake up, pour sulphuric acid 4.5ml, shake up, being positioned over room temperature, is blank with 0 pipe. measure trap according to spectrophotography (two appendix IVA of Chinese Pharmacopoeia version in 2000) at the wavelength place of 490nm.To corresponding trap, calculate regression equation with mannose ug number.
4. algoscopy
Precision is measured need testing solution 1.0ml, and from " adding 3% phenol solution 1.0ml again ", operation is in accordance with the law measured trap, by the content of regression equation calculation mannose under the sighting target directrix curve preparation.
Mannatide immunogenicity determining method (complement combined techniques);
1, test solution
A. phthalate buffer (pH7.2)
Get sodium chloride 8.5g, sodium hydrogen phosphate 0.565g and potassium dihydrogen phosphate 0.135g, add water to 1000ml and make its dissolving, add 10% Adlerika 1ml, shake up.
B.1% sheep erythrocyte suspension
The preparation of sheeps blood erythrocyte: (get glucose 20.5g, sodium citrate 8.0g, sodium chloride 4.2g in filling equivalent A Shi liquid by sheep jugular vein sterile blood sampling, citric acid 5.5g, add water to 1000mI and make dissolving, 100 ℃ the sterilization 30 minutes) sterile chamber in, 4 ℃ of preservations.
The preparation of 1% sheeps blood erythrocyte suspension: it is an amount of to get above-mentioned sheeps blood erythrocyte, and with sodium chloride injection washing three times, each centrifugal 5 minutes (2000 rev/mins), sheeps blood erythrocyte is amassed in pressure, makes 1% sheeps blood erythrocyte suspension with sodium chloride injection.Get suspension, make need testing solution for 20 times with the sodium chloride injection dilution, other gets 20 times of equivalent suspension thin ups as blank solution, according to spectrophotography (two appendix IVA of Chinese Pharmacopoeia version in 2000), wavelength place at 541nm measures, its trap should be 0.65-0.70, should regulate the concentration of 1% sheep erythrocyte suspension as overrun.
C. hemolysin and sensitization sheeps blood erythrocyte
The preparation of hemolysin: get above-mentioned hematocrit sheeps blood erythrocyte, make 25% sheeps blood erythrocyte suspension with sodium chloride injection. get 1 of rabbit, the above-mentioned sheeps blood erythrocyte suspension of intravenous injection, once a day, totally seven times, first three time 3ml, three 5ml in back, last is injected blood sampling in back seven days.Separation of serum, 56 ℃ of deactivations in .30 minute, packing is preserved below 0 ℃.
The mensuration of amboceptor unit: it is an amount of to get hemolysin, add phosphate buffer and make 1: 1000,1: 2000,1: 3000,1: 4000,1: 5000,1: 6000,1: 7000,1: 8000,1: 9000,1: 10000 diluent respectively, respectively getting 0.1ml puts in the test tube, add 1% Sanguis caprae seu ovis cell suspension 0.1ml, shake up, add dilution factor and be 1: 30 guinea pig serum (complement) 0.2ml and phosphate buffer 0.2ml, shake up, 37 ℃ of insulations 30 minutes, the high dilution of complete hemolysis pipe is 1 unit hemolysin.
The preparation of sensitization sheeps blood erythrocyte: before facing usefulness, the sheeps blood erythrocyte suspension with 2% mixes with 2 unit haemolysis rope equal-volumes, and 37 ℃ are incubated 15 minutes promptly.
Complement: get the Cavia porcellus more than three, the heart blood sampling, centrifugalize serum is preserved below 0 ℃.
The mensuration of complement unit: it is an amount of to get complement, add phosphate buffer, make 1: 40,1: 60,1: 80,1: 100,1: 120,1: 140,1: 160,1: 180 diluent respectively, respectively get 0.2ml and put in the test tube, add the 0.2ml phosphate buffer, shake up, 37 ℃ of insulations are after 30 minutes, add sensitization sheeps blood erythrocyte 0.2ml respectively, shake up, 37 ℃ are incubated 30 minutes again. and the high dilution of complete hemolysis pipe is the complement of 1 unit.
Antibody: it is an amount of to get the mannatide reference substance, add the chlorination sodium injection and make the reference substance solution immunizing rabbit that contains 10mg among every 1ml, the next day adopt ear vein injection reference substance solution once.Inject for the first time 0.2ml, for the second time respectively inject 0.5ml to the 5th time, respectively inject 1.0ml the 6th time to the tenth time, the tenth once respectively injects 2.0ml to the 15 time, and last is injected blood sampling in back three days, centrifugalize serum, 56 ℃ of deactivations in following 30 minutes, (before facing usefulness, needing 56 ℃ of deactivations once more in 30 minutes) preserved in packing below 0 ℃.
The mensuration of antibody unit: it is an amount of to get antibody, add phosphate buffer and make 1: 2,1: 4,1: 8,1: 16,1: 32.1: 64,1: 128 diluent respectively, respectively getting 0.1ml puts in the test tube, add mannatide reference substance solution 0.1ml and the 2 complement 0.2m of unit], shake up, place more than 4 hours in 4-8 ℃, put 37 ℃ of insulations 30 minutes, the high dilution of insoluble blood vessel is 1 unit antibody.Establish antigen simultaneously and (do not add antibody, replace with the 0.1ml phosphate buffer), antibody (do not add antigen, replace with the 0.1ml phosphate buffer), complement (do not add antigen, antibody, replace with the 0.2ml phosphate buffer) control tube, more than three kinds of control tube haemolysis entirely; The sensitization sheeps blood erythrocyte that other establishes (do not add antigen, antibody and complement, replace with the 0.4ml phosphate buffer) control tube is haemolysis not.
2, immunogenicity determining method
It is an amount of to get rapid glycopeptide reference substance of manna and test sample, make the reference substance solution and the need testing solution of variable concentrations according to the regulation under the medicine item, respectively getting 0.1ml puts in the test tube, add the 2 antibody 0.1ml of unit and the 2 complement 0.2ml. of unit shake up, more than 4 hours, put 37 ℃ of insulations 30 minutes in 4-8 ℃ of placement, add sensitization sheeps blood erythrocyte 0.2ml, shake up, 37 ℃ are incubated 30 minutes again.Observe the haemolysis situation of each pipe, the least concentration of insoluble blood vessel is represented the immunogenicity of mannatide.Establish antigen simultaneously and (do not add antibody, replace with the 0.1ml phosphate buffer), antibody (do not add antigen, replace with the 0.1ml phosphate buffer), complement (do not add antigen, antibody, replace) control tube with the 0.2ml phosphate buffer, more than three kinds of control tube haemolysis entirely: the sensitization sheeps blood erythrocyte that other establishes (do not add antigen, antibody and complement, replace with the 0.4ml phosphate buffer) control tube is haemolysis not.
The space flight strain is produced the preparation method of " No. three, divine boat " mannatide oral liquid:
Get the mannatide that the space flight strain is produced, add an amount of essence, correctives dissolving, add purified water, the after-filtration that stirs, fill, pressure sterilizing 105-121 ℃, 20-30 minute, packing warehouse-in after lamp inspection is qualified to full dose.
Embodiment 1:
The mannatide 1g that the space flight strain is produced, saccharin sodium 0.15g, essence 0.1ml makes 1000ml.
With the mannatide 1g that the space flight strain is produced, saccharin sodium 0.15g with a small amount of purified water dissolving, adds essence 0.1ml, adds purified water and stir evenly to 1000ml, filtration, chemically examine qualified after, embedding, 121 ℃ of flowing steam sterilizations, 30 minutes.
Embodiment 2:
The mannatide raw material 1000ml that the space flight strain is produced, active carbon 0.25g, saccharin sodium 0.15g, essence 0.1ml makes 1000ml.
Get the mannatide raw material 1000ml that the space flight strain is produced, add active carbon 0.25g, stir evenly, filter, add saccharin sodium 0.15g, add essence 0.1ml, stir evenly, chemically examine qualified after, embedding, 121 ℃ of flowing steam sterilizations, 30 minutes.
Embodiment 3:
The mannatide raw material 1000ml that the space flight strain is produced, active carbon 0.25g, protein sugar 0.8g, essence 0.1ml makes 1000ml.
Get the mannatide raw material 1000ml that the space flight strain is produced, add active carbon 0.25g, stir evenly, filter, add protein sugar 0.8g, add essence 0.1ml, stir evenly, chemically examine qualified after, embedding, 121 ℃ of flowing steam sterilizations, 30 minutes.
Embodiment 4:
The mannatide raw material 1000ml that the space flight strain is produced, active carbon 0.25g, protein sugar 0.8g,, make 1000ml.Get the mannatide raw material 1000ml that the space flight strain is produced, add active carbon 0.25g, stir evenly, filter, add protein sugar 0.8g, stir evenly, chemically examine qualified after, embedding, 121 ℃ of flowing steam sterilizations, 30 minutes.
Claims (10)
1, a kind of medicine for the treatment of chronic gastritis, it is characterized in that: it carries the reciprocation type space craft with No. 33 strains of Alpha-hemolytic streptococcus, under the specific condition of space, cause No. 33 strain hereditary properties of Alpha-hemolytic streptococcus to morph, optimize plus variant wherein, the strain of stable hereditary property, after cultivating fermentation, produce the biochemical preparation of treatment chronic gastritis, this strain is numbered CGMCCNo.1082 through China Committee for Culture Collection of Microorganisms's common micro-organisms center preservation.
2, a kind of medicine for the treatment of chronic gastritis according to claim 1, it is characterized in that: the biochemical preparation of described treatment chronic gastritis is an oral liquid, contains the mannatide 0.8g-15.0g that the space flight strain is produced among the 1000ml.
3, a kind of medicine for the treatment of chronic gastritis according to claim 1, it is characterized in that: described oral liquid is that No. 33 strains of Alpha-hemolytic streptococcus carry reciprocation type space craft, variation, the strain after preferred, through cultivating the production stock solution of fermentation, add other attached material.
4, a kind of medicine for the treatment of chronic gastritis according to claim 1, it is characterized in that: described oral liquid is that No. 33 strains of Alpha-hemolytic streptococcus carry reciprocation type space craft, variation, the strain after preferred, through cultivating the production stock solution of fermentation, add the purified water dissolving and stir evenly.
5, a kind of medicine for the treatment of chronic gastritis according to claim 1 is characterized in that: described attached material be essence and, smart sodium, protein sugar.
6, a kind of medicine for the treatment of chronic gastritis according to claim 1, it is characterized in that: described attached material is an active carbon.
7, a kind of medicine for the treatment of chronic gastritis according to claim 1, it is characterized in that: the preparation method of described mannatide is; Preferred alpha-Hemolytic streptococcus 33 strains carry out space treatment, and No. 33 bacterium pearls of alpha-Hemolytic streptococcus of the meticulous selection-breeding of process space flight are as the production strain preparation; Through one grade fermemtation and second order fermentation, fermentation liquid to be purified, final production goes out the mannatide that the space flight strain is produced.
8, a kind of medicine for the treatment of chronic gastritis according to claim 1 is characterized in that: described strain preparation:
A. inclined-plane seed culture medium: Carnis Bovis seu Bubali cream 0.2-0.8%, yeast extract 0.2-0.8%, peptone 0.3-0.8%, glucose 0.1-0.8%, sodium chloride 0.2-0.6%, agar 1-5%, sheep blood 5-10%; PH7.2-7.4;
105-125 ℃ of inclined-plane seed culture medium sterilising temp, 30 minutes time, steam pressure 0.11-0.14Mpa;
Unpacking strain cryovial, with aseptic broth bouillon dilution, access blood inclined-plane under aseptic condition, inoculate rearmounted 25-40 ℃ constant temperature culture 24-30 hour;
B. meat soup seed culture medium: Carnis Bovis seu Bubali cream 0.2-0.8%, yeast extract 0.2-0.8%, peptone 0.3-0.8%, glucose 0.1-0.8%, sodium chloride 0.2-0.6%; PH7.0-7.4;
105-125 ℃ of meat soup seed culture medium sterilising temp, 30 minutes time, steam pressure 0.11-0.14Mpa; Cultured slant strains is pressed the 1-9% inoculum concentration insert in the meat soup seed culture medium under aseptic condition, 25-40 ℃ constant temperature culture 10-30 hour.
9, a kind of medicine for the treatment of chronic gastritis according to claim 1 is characterized in that:
Described sweat fermentation medium; Carnis Bovis seu Bubali cream 0.2-0.8%, yeast extract 0.2-0.8%, peptone 0.3-0.8%, glucose 0.1-0.9%, sodium chloride 0.2-0.6%; 105-125 ℃ of fermentation medium sterilising temp, 30 minutes time, steam pressure 0.11-0.14Mpa;
A. one grade fermemtation jar: good meat soup strain is pressed the 1-10% inoculum concentration insert first class seed pot under aseptic condition, at 25-40 ℃ of constant temperature culture 10-50 hour, tank pressure was no more than 0.02Mpa, and ventilation is advisable can stir culture fluid, fully stirred continuously;
B. second order fermentation jar: the one grade fermemtation culture fluid is pressed the 2-20% inoculum concentration insert fermentation tank under aseptic condition, at 25-40 ℃ of constant temperature culture 20-100 hour, tank pressure was no more than 0.02Mpa; Jar is put in deactivation, and deactivation is adopted to heat and made the fermentation liquid temperature reach 70-120 ℃, is incubated 20-60 minute, and cooling is left standstill.
10, a kind of medicine for the treatment of chronic gastritis according to claim 1 is characterized in that:
Described leaching process;
A, fermentation liquid concentrate, and make concentrated solution volume and fermentating liquid volume ratio be controlled at 1: 15-1: 20 or be determined by circumstances;
The concentrated solution of b, fermentation liquid adds 80-99% ethanol, and the volume ratio is controlled at 1: 1.5-1: 5.5 or be determined by circumstances, fully stir leave standstill after, centrifugal removal supernatant, the precipitation dissolved in distilled water, accent pH1.0-5.0 obtains lysate and lysate is left standstill;
C, the more centrifugal removal impurity of lysate is obtained supernatant, accurately measure the supernatant volume, calculate required amount of alcohol, ethanol is slowly joined in the supernatant, and fully stir, leave standstill the centrifugal removal supernatant in back and obtain precipitate by the supernatant stereometer;
D, precipitate reuse dissolved in distilled water are transferred pH, centrifugal, and supernatant adds ethanol precipitation again, such technology repeatable operation to content detection qualified till, the precipitate that obtains is the mannatide crude product that the space flight strain is produced; Promptly got the mannan peptide product that the space flight strain is produced in vacuum drying 3-8 hour.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2003101222400A CN1331531C (en) | 2003-12-31 | 2003-12-31 | Medicine for treating chronic gastritis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2003101222400A CN1331531C (en) | 2003-12-31 | 2003-12-31 | Medicine for treating chronic gastritis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1634555A true CN1634555A (en) | 2005-07-06 |
| CN1331531C CN1331531C (en) | 2007-08-15 |
Family
ID=34844456
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2003101222400A Expired - Fee Related CN1331531C (en) | 2003-12-31 | 2003-12-31 | Medicine for treating chronic gastritis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1331531C (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100368015C (en) * | 2003-12-31 | 2008-02-13 | 西安亨通光华制药有限公司 | Medicine for relieving drunk |
| CN100408087C (en) * | 2003-12-31 | 2008-08-06 | 西安亨通光华制药有限公司 | Medicine for treating bronchial asthma |
| CN100408089C (en) * | 2005-12-31 | 2008-08-06 | 西安亨通光华制药有限公司 | Animal medicine capable of resisting multiple irritated stress of chicken |
| CN100450543C (en) * | 2005-12-31 | 2009-01-14 | 西安亨通光华制药有限公司 | Animal medicine capable of increasing immunologic function of livestock and birds |
| CN101348783B (en) * | 2008-06-23 | 2011-04-27 | 北京东方红航天生物技术股份有限公司 | Method for preparing Saccharomyces cerevisiae product using aerospace biological technology and product thereof |
| CN101062405B (en) * | 2006-04-28 | 2012-06-06 | 西安亨通光华制药有限公司 | Medicine for animals for treating and preventing avian influenza |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1047078C (en) * | 1993-06-29 | 1999-12-08 | 杨延珍 | Process for preparing anticancer medicine "Liantangsu" its preparation |
| CN1075377C (en) * | 1998-12-09 | 2001-11-28 | 黄子垒 | Composite mannosans peptides oral liquor |
| CN1429558A (en) * | 2003-01-24 | 2003-07-16 | 海南豪迈医药有限公司 | Mannosan peptide injection and its preparation and use method |
| CN1175899C (en) * | 2003-03-31 | 2004-11-17 | 成都利尔药业有限公司 | Medicine composition and preparation and use thereof |
| CN1172952C (en) * | 2003-03-31 | 2004-10-27 | 成都利尔药业有限公司 | Mannosan peptide and its prepn and use |
| CN1457880A (en) * | 2003-04-26 | 2003-11-26 | 南昌弘益科技有限公司 | Polyresistin dripping pill and its preparing method for immunodeficiency |
-
2003
- 2003-12-31 CN CNB2003101222400A patent/CN1331531C/en not_active Expired - Fee Related
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100368015C (en) * | 2003-12-31 | 2008-02-13 | 西安亨通光华制药有限公司 | Medicine for relieving drunk |
| CN100408087C (en) * | 2003-12-31 | 2008-08-06 | 西安亨通光华制药有限公司 | Medicine for treating bronchial asthma |
| CN100408089C (en) * | 2005-12-31 | 2008-08-06 | 西安亨通光华制药有限公司 | Animal medicine capable of resisting multiple irritated stress of chicken |
| CN100450543C (en) * | 2005-12-31 | 2009-01-14 | 西安亨通光华制药有限公司 | Animal medicine capable of increasing immunologic function of livestock and birds |
| CN101062405B (en) * | 2006-04-28 | 2012-06-06 | 西安亨通光华制药有限公司 | Medicine for animals for treating and preventing avian influenza |
| CN101348783B (en) * | 2008-06-23 | 2011-04-27 | 北京东方红航天生物技术股份有限公司 | Method for preparing Saccharomyces cerevisiae product using aerospace biological technology and product thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1331531C (en) | 2007-08-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110964650B (en) | Bacterial strain for preventing and treating metabolic diseases and application thereof | |
| CN1931879A (en) | New use of tremella heteropolysaccharide or its extract | |
| CN1916028A (en) | Polysaccharide outside cyst of lactobacillus casei and crude product, prepartion method and application | |
| CN105132328B (en) | It is a kind of can preventing gastric ulcer lactobacillus fermenti Lactobacillus fermentum strain suo and application thereof | |
| CN1663604A (en) | Spray for treating chronic pharyngitis | |
| CN1644681A (en) | Plant lactobacillaceae and use thereof | |
| CN1634555A (en) | Medicine for treating chronic gastritis | |
| CN1880471A (en) | Method for detecting bifidobacteria in milk product | |
| CN1957956A (en) | Composition of multiple fungus possessing effects of anti tumour and adjusting immunity preparation method, and usage | |
| CN1663602A (en) | Medicine for treating neurasthenia | |
| CN113957007B (en) | Inactivated vaccine for mycoplasma synoviae | |
| CN105154362A (en) | Lactobacillus fermentum suo strain capable of preventing gastrohelcoma and health-care application thereof | |
| CN1634557A (en) | Medicine for treating ulcerative colitis | |
| CN1218962C (en) | Somatostatin yolk antibody and its preparing process | |
| CN101074260A (en) | Production of hygrophilous monospermous bacterium main-protective antigen univalent and multivalent vitelline antibody and use in aquatic animal | |
| CN1175899C (en) | Medicine composition and preparation and use thereof | |
| CN1663608A (en) | Medicine for treating infantile anorexia | |
| CN1634564A (en) | Preparation and use of mannan peptide oral granule | |
| CN1239694C (en) | Space mutagenesis high production and highly performance bacterial and use thereof | |
| CN1634560A (en) | Medicine for treating bronchial asthma | |
| CN1209163C (en) | Meningococcal vaccine and its preparing method | |
| CN1634556A (en) | Medicine for treating peptic ulcer | |
| CN1634561A (en) | Medicine for treating oral ulcer | |
| CN1634558A (en) | Medicine for treating Parkinson's disease | |
| CN1280409C (en) | Health protecting product composition with liver protecting and blood fat regulating function and its preparation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: XI AN HENGTONG GUANGHUA PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: ZHAO HENG Effective date: 20080627 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20080627 Address after: E, International Building, No. 17, hi tech development road, 27 West, Shaanxi, Xi'an Patentee after: Xi'an Hengtong Guanghue Pharmaceutical Co.,Ltd Address before: No. 27, hi tech Zone, Shaanxi hi tech Zone, Xi'an Province, E Yang building, 17 floor Patentee before: Zhao Heng |
|
| PP01 | Preservation of patent right |
Effective date of registration: 20081225 Pledge (preservation): Preservation |
|
| PD01 | Discharge of preservation of patent |
Date of cancellation: 20091225 Pledge (preservation): Preservation registration |
|
| PP01 | Preservation of patent right |
Effective date of registration: 20100611 Granted publication date: 20070815 |
|
| PD01 | Discharge of preservation of patent |
Date of cancellation: 20101211 Granted publication date: 20070815 |
|
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20070815 Termination date: 20111231 |